{"@context":"https://schema.org","@type":"DataCatalog","name":"The Peptide Examiner — Peptide Registry","url":"https://thepeptideexaminer.com/data/peptides.json","dateModified":"2026-04-25T12:31:02.695Z","peptides":[{"slug":"semaglutide","name":"Semaglutide","aliases":["Ozempic","Wegovy","Rybelsus"],"category":"glp1","status":"approved","fdaStatus":"FDA approved 2017 (T2D), 2021 (obesity)","firstSynthesized":"2012","primaryResearch":"Weight / diabetes","canonicalUrl":"https://thepeptideexaminer.com/research/semaglutide"},{"slug":"tirzepatide","name":"Tirzepatide","aliases":["Mounjaro","Zepbound"],"category":"glp1","status":"approved","fdaStatus":"FDA approved 2022 (T2D), 2023 (obesity)","firstSynthesized":"2016","primaryResearch":"Weight / diabetes","canonicalUrl":"https://thepeptideexaminer.com/research/tirzepatide"},{"slug":"retatrutide","name":"Retatrutide","aliases":["LY-3437943"],"category":"glp1","status":"investigational","fdaStatus":"Phase 3 (Eli Lilly, 2025–)","firstSynthesized":"2022","primaryResearch":"Weight / obesity","canonicalUrl":"https://thepeptideexaminer.com/research/retatrutide"},{"slug":"cagrilintide","name":"Cagrilintide","aliases":["AM833"],"category":"glp1","status":"investigational","fdaStatus":"Phase 3 (Novo Nordisk) paired with semaglutide","firstSynthesized":null,"primaryResearch":"Weight / metabolic","canonicalUrl":"https://thepeptideexaminer.com/research/cagrilintide"},{"slug":"orforglipron","name":"Orforglipron","aliases":["LY-3502970"],"category":"glp1","status":"investigational","fdaStatus":"Oral GLP-1; Phase 3 (2026)","firstSynthesized":null,"primaryResearch":"Weight / diabetes","canonicalUrl":"https://thepeptideexaminer.com/research/orforglipron"},{"slug":"bpc-157","name":"BPC-157","aliases":["Body Protection Compound","PL 14736"],"category":"healing","status":"ruo","fdaStatus":"Category 2 (Feb 2026 HHS proposed removal)","firstSynthesized":null,"primaryResearch":"Tissue repair / GI","canonicalUrl":"https://thepeptideexaminer.com/research/bpc-157"},{"slug":"tb-500","name":"TB-500","aliases":["Thymosin Beta-4 fragment","TB4"],"category":"healing","status":"ruo","fdaStatus":"Category 2 (Feb 2026 HHS proposed removal)","firstSynthesized":null,"primaryResearch":"Tissue repair","canonicalUrl":"https://thepeptideexaminer.com/research/tb-500"},{"slug":"kpv","name":"KPV","aliases":["Lys-Pro-Val"],"category":"healing","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"Anti-inflammatory","canonicalUrl":"https://thepeptideexaminer.com/research/kpv"},{"slug":"cjc-1295","name":"CJC-1295","aliases":["Modified GRF (1-29)","DAC"],"category":"growth","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"GH secretagogue","canonicalUrl":"https://thepeptideexaminer.com/research/cjc-1295"},{"slug":"ipamorelin","name":"Ipamorelin","aliases":[],"category":"growth","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"GH secretagogue","canonicalUrl":"https://thepeptideexaminer.com/research/ipamorelin"},{"slug":"sermorelin","name":"Sermorelin","aliases":["GHRH 1-29"],"category":"growth","status":"approved","fdaStatus":"Historical FDA approval; now compounded","firstSynthesized":null,"primaryResearch":"GH deficiency","canonicalUrl":"https://thepeptideexaminer.com/research/sermorelin"},{"slug":"tesamorelin","name":"Tesamorelin","aliases":["Egrifta"],"category":"growth","status":"approved","fdaStatus":"FDA approved 2010 (HIV-lipodystrophy)","firstSynthesized":null,"primaryResearch":"GH / fat redistribution","canonicalUrl":"https://thepeptideexaminer.com/research/tesamorelin"},{"slug":"mk-677","name":"MK-677","aliases":["Ibutamoren","Nutrobal"],"category":"growth","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"GH secretagogue","canonicalUrl":"https://thepeptideexaminer.com/research/mk-677"},{"slug":"ghk-cu","name":"GHK-Cu","aliases":["Copper peptide","Glycyl-L-histidyl-L-lysine copper"],"category":"longevity","status":"supplement","fdaStatus":"Cosmetic approval; injectable Category 2","firstSynthesized":null,"primaryResearch":"Skin / hair / tissue","canonicalUrl":"https://thepeptideexaminer.com/research/ghk-cu"},{"slug":"epitalon","name":"Epitalon","aliases":["Epithalon","Ala-Glu-Asp-Gly"],"category":"longevity","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"Longevity / circadian","canonicalUrl":"https://thepeptideexaminer.com/research/epitalon"},{"slug":"mots-c","name":"MOTS-c","aliases":["Mitochondrial-derived peptide"],"category":"longevity","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"Metabolic / mitochondrial","canonicalUrl":"https://thepeptideexaminer.com/research/mots-c"},{"slug":"thymosin-alpha-1","name":"Thymosin Alpha-1","aliases":["Zadaxin"],"category":"longevity","status":"investigational","fdaStatus":"Approved in 30+ countries; US investigational","firstSynthesized":null,"primaryResearch":"Immune / antiviral","canonicalUrl":"https://thepeptideexaminer.com/research/thymosin-alpha-1"},{"slug":"semax","name":"Semax","aliases":[],"category":"cognitive","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"Cognitive / neuroprotection","canonicalUrl":"https://thepeptideexaminer.com/research/semax"},{"slug":"selank","name":"Selank","aliases":[],"category":"cognitive","status":"ruo","fdaStatus":null,"firstSynthesized":null,"primaryResearch":"Cognitive / anxiety","canonicalUrl":"https://thepeptideexaminer.com/research/selank"},{"slug":"pt-141","name":"PT-141","aliases":["Bremelanotide","Vyleesi"],"category":"sexual","status":"approved","fdaStatus":"FDA approved 2019 (HSDD, women)","firstSynthesized":null,"primaryResearch":"Sexual function","canonicalUrl":"https://thepeptideexaminer.com/research/pt-141"}]}